Ex­perts talk IRA im­pacts as CMS an­nounces it will pub­lish first 10 drugs up for ne­go­ti­a­tion in Sep­tem­ber

Ex­perts went back and forth on the im­pacts of the In­fla­tion Re­duc­tion Act, or IRA, on the bio­phar­ma in­dus­try in a vir­tu­al pan­el host­ed by End­points News at JP Mor­gan Wednes­day.

The ma­jor drug pric­ing re­form passed last year and al­lowed Medicare drug price ne­go­ti­a­tions for the first time ever. It al­so capped se­nior drug ex­pens­es at $2,000 a year and in­sulin costs at $35 a month.

Wednes­day morn­ing, the Cen­ters for Medicare & Med­ic­aid Ser­vices (CMS) an­nounced its time­line for ne­go­ti­a­tions. In a me­dia call, CMS ad­min­is­tra­tor Chiq­ui­ta Brooks-La­Sure said, “Our ac­tions this year will cul­mi­nate in the an­nounce­ment of a list of 10 part D, high-spend brand name drugs to par­tic­i­pate in the ne­go­ti­a­tion pro­gram.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.